Adjuvant chemotherapy for gastric cancer: a comprehensive review |
| |
Authors: | Yoshihiko Maehara Hideo Baba Keizo Sugimachi |
| |
Institution: | (1) Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan, JP;(2) Department of Surgery, National Kyushu Cancer Center, Fukuoka, Japan, JP |
| |
Abstract: | The role of adjuvant chemotherapy in gastric cancer has been studied extensively over the past three decades in an attempt
to further improve the prognosis of patients with gastric cancer who have undergone curative surgery. To date, no definitive
conclusions have been drawn from randomized clinical trials of adjuvant chemotherapy for gastric cancer, because few studies
have shown a significant positive impact on survival as compared with surgery alone. The negative results of most previous
clinical studies do not necessarily mean that the adjuvant chemotherapy approach to treatment of gastric cancer does not work.
Recent published reports of meta-analyses concerning adjuvant chemotherapy of gastric cancer revealed small but clear survival
advantages for adjuvant therapy over surgery alone. The positive data from meta-analyses suggests that there are potential
survival advantages of adjuvant chemotherapy, but this must be proven in the future by well-designed clinical trials that
compare adjuvant chemotherapy with surgery alone, in which sufficient numbers of patients are enrolled and effective chemotherapeutic
regimens with appropriate dose intensity are employed. Newly developed anticancer agents and/or newer therapeutic combinations
or strategies (neoadjuvant chemotherapy, chemoradiotherapy, intraperitoneal chemotherapy) have the potential to benefit high-risk
patients.
Received: June 6, 2001 / Accepted: August 24, 2001 |
| |
Keywords: | Adjuvant chemotherapy Gastric cancer Chemoimmunotherapy |
本文献已被 SpringerLink 等数据库收录! |
|